Cortisol
From DrugPedia: A Wikipedia for Drug discovery
(Difference between revisions)
| (One intermediate revision not shown.) | |||
| Line 1: | Line 1: | ||
| - | Hydrocortisone(Cortisol) | + | '''Hydrocortisone(Cortisol)''' |
| - | Pubchem(5754) | + | '''Pubchem(5754)''' |
The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. | The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. | ||
| Line 12: | Line 12: | ||
0 POOR | 0 POOR | ||
| - | Pathway(C00735,D00088) | + | '''KEGG Pathway'''(C00735,D00088) |
| - | C21-Steroid hormone metabolism | + | *C21-Steroid hormone metabolism |
| - | Neuroactive ligand-receptor interaction | + | *Neuroactive ligand-receptor interaction |
| - | Prostate cancer | + | *Prostate cancer |
| - | Target glucocorticoid receptor | + | '''Target''' glucocorticoid receptor |
| - | + | ||
| + | '''Activity''' Glucocorticoid | ||
| + | |||
| + | {| border="1;width:100%; height:200px;style=text-align:center" | ||
| + | |+'''Table I:''' | ||
| + | |- | ||
| + | ! style="background:brown; color:white" |MMDB ID | ||
| + | ! style="background:brown; color:white" |PDB ID | ||
| + | ! style="background:brown; color:white" |Reference | ||
| + | |- | ||
|59369 | |59369 | ||
|2Q1V | |2Q1V | ||
| Line 73: | Line 81: | ||
|- | |- | ||
|} | |} | ||
| - | Organism | + | {| border="1;width:100%; height:200px;style=text-align:center" |
| + | |+'''Table I:''' | ||
| + | |- | ||
| + | ! style="background:brown; color:white" |Organism | ||
| + | ! style="background:brown; color:white" |Test Type | ||
| + | ! style="background:brown; color:white" |Route | ||
| + | ! style="background:brown; color:white" |Reported Dose (Normalized Dose) | ||
| + | ! style="background:brown; color:white" |Effect | ||
| + | ! style="background:brown; color:white" |Source | ||
| + | |- | ||
|man | |man | ||
|TDLo | |TDLo | ||
| Line 84: | Line 101: | ||
|LD50 | |LD50 | ||
|subcutaneous | |subcutaneous | ||
| - | |> 500mg/kg (500mg/kg) | + | |> 500mg/kg (500mg/kg) |
| + | | | ||
|Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 24(3), Pg. 26, 1990. | |Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 24(3), Pg. 26, 1990. | ||
| + | |- | ||
|rat | |rat | ||
|LD50 | |LD50 | ||
|intraperitoneal | |intraperitoneal | ||
| - | |150mg/kg (150mg/kg) | + | |150mg/kg (150mg/kg) |
| + | | | ||
|Japanese Journal of Pharmacology. Vol. 21, Pg. 377, 1971. | |Japanese Journal of Pharmacology. Vol. 21, Pg. 377, 1971. | ||
|- | |- | ||
| Line 95: | Line 115: | ||
|LD50 | |LD50 | ||
|subcutaneous | |subcutaneous | ||
| - | |449mg/kg (449mg/kg) | + | |449mg/kg (449mg/kg) |
| + | | | ||
|Toxicology and Applied Pharmacology. Vol. 8, Pg. 250, 1966. | |Toxicology and Applied Pharmacology. Vol. 8, Pg. 250, 1966. | ||
|- | |- | ||
|} | |} | ||
Current revision
Hydrocortisone(Cortisol)
Pubchem(5754)
The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.
Lipinski’s “Rule of Five” Prediction for a Compound’s ABSORPTION OR PERMEABILITY PROPERTIES 4 GOOD 3 INDETERMINATE 2 INDETERMINATE 1 INDETERMINATE 0 POOR
KEGG Pathway(C00735,D00088)
- C21-Steroid hormone metabolism
- Neuroactive ligand-receptor interaction
- Prostate cancer
Target glucocorticoid receptor
Activity Glucocorticoid
| MMDB ID | PDB ID | Reference |
|---|---|---|
| 59369 | 2Q1V | Ortlund EA, Bridgham JT, Redinbo MR, Thornton JWCrystal structure of an ancient protein: evolution by conformational epistasisScience v317, p.1544-1548 |
| 59811 | 2V95 | Klieber MA, Underhill C, Hammond GL, Muller YACorticosteroid-binding globulin, a structural basis for steroid transport and proteinase-triggered releaseJ. Biol. Chem. v282, p.29594-29603 |
| 64401 | 2VDY | Zhou A, Wei Z, Stanley PL, Read RJ, Stein PE, Carrell RWThe S-to-R transition of corticosteroid-binding globulin and the mechanism of hormone releaseJ. Mol. Biol. v380, p.244-251 |
| Physical Property | Value | Units | Temp (deg C) | Source |
|---|---|---|---|---|
| Melting Point | 220 | deg C | EXP | |
| Water Solubility | 320 | mg/L | 25 | EXP |
| Vapor Pressure | 1.35E-13 | mm Hg | 25 | EST |
| Henry's Law Constant | 5.77E-08 | atm-m3/mole | 25 | EST |
| Atmospheric OH Rate Constant | 1.14E-10 | cm3/molecule-sec | 25 | EST |
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| man | TDLo | oral | 400mg/kg/10D- (400mg/kg) | BEHAVIORAL: CHANGES IN PSYCHOPHYSIOLOGICAL TESTS | Psychopharmacology Vol. 145, Pg. 260, 1999. |
| mouse | LD50 | subcutaneous | > 500mg/kg (500mg/kg) | Khimiko-Farmatsevticheskii Zhurnal. Chemical Pharmaceutical Journal. For English translation, see PCJOAU. Vol. 24(3), Pg. 26, 1990. | |
| rat | LD50 | intraperitoneal | 150mg/kg (150mg/kg) | Japanese Journal of Pharmacology. Vol. 21, Pg. 377, 1971. | |
| rat | LD50 | subcutaneous | 449mg/kg (449mg/kg) | Toxicology and Applied Pharmacology. Vol. 8, Pg. 250, 1966. |
